Pulmatrix Stockholders Approve Merger with Cullgen

Pulmatrix ( (PULM) ) has issued an update.

On June 16, 2025, Pulmatrix held a special meeting where stockholders approved several proposals related to a merger with Cullgen. Key approvals included the issuance of new shares, a reverse stock split, an increase in authorized shares, and the adoption of Cullgen’s stock incentive and employee stock purchase plans. These decisions are expected to significantly impact Pulmatrix’s capital structure and governance, positioning the company for strategic growth and enhanced market competitiveness.

Spark’s Take on PULM Stock

According to Spark, TipRanks’ AI Analyst, PULM is a Neutral.

Pulmatrix’s overall score reflects significant profitability challenges and negative cash flows, despite a strong balance sheet with no debt. Technical indicators suggest moderate upward momentum, yet the negative valuation metrics due to ongoing losses detract from its appeal.

To see Spark’s full report on PULM stock, click here.

More about Pulmatrix

Pulmatrix operates in the biopharmaceutical industry, focusing on developing inhaled therapies for respiratory diseases. The company is known for its innovative drug delivery platform, which aims to address unmet medical needs in respiratory health.

Average Trading Volume: 18,709

Technical Sentiment Signal: Buy

Current Market Cap: $28.52M

For an in-depth examination of PULM stock, go to TipRanks’ Overview page.